NCT06505512 A Study of Enterorenal Syndrome Assessed by Gastrointestinal Ultrasound Combined with Renal Artery Resistance Index
| NCT ID | NCT06505512 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Zhangzhou Municipal Hospital |
| Condition | Sepsis |
| Study Type | OBSERVATIONAL |
| Enrollment | 74 participants |
| Start Date | 2024-01-19 |
| Primary Completion | 2025-02-25 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 74 participants in total. It began in 2024-01-19 with a primary completion date of 2025-02-25.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
In this study, the patients with sepsis caused by abdominal infection were divided into survival group and death group by ultrasound examination of gastrointestinal function, superior mesenteric artery blood flow, and renal artery resistance index. The cross-sectional area of gastric antrum, average time flow rate of superior mesenteric artery, colon diameter, colon peristalsis frequency, and renal artery resistance index of the two groups were compared to determine the progression of entero-renal syndrome as soon as possible. To provide reliable objective basis for clinical decision-making, in order to improve the success rate of rescue.
Eligibility Criteria
Inclusion Criteria: * Patients diagnosed with intra-abdominal infections * Patients with sepsis or septic shock Exclusion Criteria: * Patients with open chest or abdominal injury * Patients with advanced tumor * Patients with uremia * Pregnant women
Contact & Investigator
Hui Jiang, Dr.
PRINCIPAL INVESTIGATOR
the Ethnics Committee of Zhangzhou Municipal Hospital of Fujian Province
Frequently Asked Questions
Who can join the NCT06505512 clinical trial?
This trial is open to participants of all sexes, aged 14 Years or older, up to 85 Years, studying Sepsis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06505512 currently recruiting?
Yes, NCT06505512 is actively recruiting participants. Contact the research team at cdkant@163.com for enrollment information.
Where is the NCT06505512 trial being conducted?
This trial is being conducted at Zhangzhou, China.
Who is sponsoring the NCT06505512 clinical trial?
NCT06505512 is sponsored by Zhangzhou Municipal Hospital. The principal investigator is Hui Jiang, Dr. at the Ethnics Committee of Zhangzhou Municipal Hospital of Fujian Province. The trial plans to enroll 74 participants.